The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q1 2024 call → NOWe need to determine if management conveys that the reported results do not represent the business as it is actually running today, i.e., the period is stale relative to the operating present. Look for repeated or substantial indications that the just-reported numbers describe a company already left behind by what is happening now. In the transcript, management discusses several things: disappointing Q1 revenue, slower conversion of new accounts, burn business below expectations, but also mentions initiatives like RECELL GO nearing approval, PermeaDerm launch, international expansion, etc. However, the key is whether they explicitly say that the reported period does not reflect the current state of the business. They do mention that some things like PermeaDerm launched in late March, so minimal revenue in Q1, but they expect it to grow. They also mention RECELL GO approval expected soon, which will boost second half. But is that a claim that the business has already changed? They say "we are ready to go" for RECELL GO, but it's not yet approved. They also talk about VAC approvals expected in Q2, but that's future. The question asks: does management convey that the reported results do not represent the business the company is actually running today? That is, the business as it stands today is ahead of the business as it appears in the reported period. Management must be drawing attention to that gap grounded in things already real. In the call, management acknowledges the quarter was disappointing and below expectations. They attribute it to slower VAC conversions and burn admissions. They then talk about steps taken: enhanced coverage strategy, RECELL GO nearing approval, PermeaDerm launch, etc. But do they say that the current business is already ahead of the reported numbers? They give guidance for Q2 and full year, which implies they expect improvement. But that's forward-looking, not necessarily that the current business is already different. They mention that PermeaDerm launched in late March, so revenue is less than 1% in Q1, but they expect it to increase. That is a concrete thing that started late in the period, so the period doesn't include its full effect. Similarly, RECELL GO is not yet approved, so it's not in the period. But they say "we are ready to go" and expect approval May 30, which is after the period. So that's future.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.